TY - JOUR
T1 - Prolonged topotecan infusion with cisplatin in the first-line treatment of ovarian cancer
T2 - An NYGOG and ECOG study
AU - Hochster, Howard S.
AU - Plimack, Elizabeth R.
AU - Mandeli, John
AU - Wadler, Scott
AU - Runowicz, Carolyn
AU - Goldberg, Gary
AU - Speyer, James
AU - Wallach, Robert
AU - Muggia, Franco
N1 - Funding Information:
Presented in part at the American Society of Clinical Oncology, 2001; supported in part by NIH Grants: CA16087, CA76642, CA21115(-27) and N01-CM-07003-74S.
PY - 2006/2
Y1 - 2006/2
N2 - Objective. To determine the toxicity and efficacy of combined therapy with cisplatin and prolonged infusion topotecan as front line therapy in women with epithelial ovarian cancer. Patients and methods. Women with previously untreated, measurable and non-measurable epithelial ovarian cancer, stages Ic-IV were eligible. Patients were treated with cisplatin 75 mg/m2 on day 1, followed by topotecan 0.3 to 0.4 mg/m2/day given as a continuous infusion over 14-21 days, every 28 days. Dose levels and duration of infusion were adjusted for toxicity as appropriate. Patients were evaluated for response to treatment and treatment toxicity by standard NYGOG criteria. Results. Sixty patients were enrolled. Among the 20 patients with post-surgical residual disease >2 cm, 80% [95% CI (56.3%, 94.3%)] demonstrated an objective response to therapy. The median progression-free survival for all 60 patients enrolled was 19.3 months with a median overall survival of 45.6 months given the median follow-up of 55 months (range 6-81 months). Five year survival is estimated to be 41%. Toxicity was observed in the first four patients treated with topotecan (0.4 mg/m2/day × 21 days) and dosing was continued at 0.3 mg/m2/day × 14 days thereafter. Of the 56 patients treated at the amended dose level, marrow suppression continued to be dose-limiting, with 86% of patients experiencing grade 3 or 4 neutropenia, 55% experiencing grade 3 or 4 thrombocytopenia and 50% of patients experiencing grade 3 or 4 anemia. Nonetheless, only 11/245 cycles administered were associated with febrile neutropenia and/or infection (8 port-related). Other non-hematologic toxicity was as expected. There were no treatment-related deaths. Conclusion. This large, multicenter phase II study of prolonged infusion topotecan in combination with cisplatin demonstrated similar response, time to progression and survival compared with reported results of taxane and platinum combinations. Hematologic toxicity was greater but tolerated. Further studies investigating topotecan in combination with platinum therapy as a first line agent are warranted.
AB - Objective. To determine the toxicity and efficacy of combined therapy with cisplatin and prolonged infusion topotecan as front line therapy in women with epithelial ovarian cancer. Patients and methods. Women with previously untreated, measurable and non-measurable epithelial ovarian cancer, stages Ic-IV were eligible. Patients were treated with cisplatin 75 mg/m2 on day 1, followed by topotecan 0.3 to 0.4 mg/m2/day given as a continuous infusion over 14-21 days, every 28 days. Dose levels and duration of infusion were adjusted for toxicity as appropriate. Patients were evaluated for response to treatment and treatment toxicity by standard NYGOG criteria. Results. Sixty patients were enrolled. Among the 20 patients with post-surgical residual disease >2 cm, 80% [95% CI (56.3%, 94.3%)] demonstrated an objective response to therapy. The median progression-free survival for all 60 patients enrolled was 19.3 months with a median overall survival of 45.6 months given the median follow-up of 55 months (range 6-81 months). Five year survival is estimated to be 41%. Toxicity was observed in the first four patients treated with topotecan (0.4 mg/m2/day × 21 days) and dosing was continued at 0.3 mg/m2/day × 14 days thereafter. Of the 56 patients treated at the amended dose level, marrow suppression continued to be dose-limiting, with 86% of patients experiencing grade 3 or 4 neutropenia, 55% experiencing grade 3 or 4 thrombocytopenia and 50% of patients experiencing grade 3 or 4 anemia. Nonetheless, only 11/245 cycles administered were associated with febrile neutropenia and/or infection (8 port-related). Other non-hematologic toxicity was as expected. There were no treatment-related deaths. Conclusion. This large, multicenter phase II study of prolonged infusion topotecan in combination with cisplatin demonstrated similar response, time to progression and survival compared with reported results of taxane and platinum combinations. Hematologic toxicity was greater but tolerated. Further studies investigating topotecan in combination with platinum therapy as a first line agent are warranted.
KW - First-line chemotherapy
KW - Infusional chemotherapy
KW - Ovarian cancer
KW - Platinum
KW - Topotecan
UR - http://www.scopus.com/inward/record.url?scp=30444457230&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=30444457230&partnerID=8YFLogxK
U2 - 10.1016/j.ygyno.2005.08.059
DO - 10.1016/j.ygyno.2005.08.059
M3 - Article
C2 - 16253316
AN - SCOPUS:30444457230
SN - 0090-8258
VL - 100
SP - 324
EP - 329
JO - Gynecologic Oncology
JF - Gynecologic Oncology
IS - 2
ER -
